Robier Aguillon Prada - Faculty - The University of Texas Health Science Center at Houston (UTHealth) | LinkedIn
![1568636025 NPI Number | ROBIER A AGUILLON PRADA M.D. | CLEVELAND, OH | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023 1568636025 NPI Number | ROBIER A AGUILLON PRADA M.D. | CLEVELAND, OH | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023](https://www.hipaaspace.com/medical_billing/coding/national_provider_identifier/codes/npi_1568636025.png)
1568636025 NPI Number | ROBIER A AGUILLON PRADA M.D. | CLEVELAND, OH | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023
Robier Aguillon Prada - Faculty - The University of Texas Health Science Center at Houston (UTHealth) | LinkedIn
Robier Aguillon Prada - Faculty - The University of Texas Health Science Center at Houston (UTHealth) | LinkedIn
Robier Aguillon Prada - Faculty - The University of Texas Health Science Center at Houston (UTHealth) | LinkedIn
Robier Aguillon Prada - Faculty - The University of Texas Health Science Center at Houston (UTHealth) | LinkedIn
![Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical](https://onlinelibrary.wiley.com/cms/asset/24ace4f9-46c8-4eef-9c4f-0f38027b20a3/clc23451-fig-0002-m.jpg)
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
![PDF) Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) PDF) Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)](https://i1.rgstatic.net/publication/343856261_Canakinumab_to_reduce_deterioration_of_cardiac_and_respiratory_function_in_SARS-CoV-2_associated_myocardial_injury_with_heightened_inflammation_canakinumab_in_Covid-19_cardiac_injury_The_three_C_study/links/5f5d9d1e299bf1d43cff9a3e/largepreview.png)